Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Joint Bone Spine|September 23, 2022
Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritisCarla G S Saad, Matheus S R Silva, Perceval D Sampaio-Barros, et al.
The Lancet. HIV|March 26, 2022
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort studyLucas C Netto, Karim Y Ibrahim, Camila M Picone, et al.
Clinics (Sao Paulo, Brazil)|December 18, 2022
Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster doseRosa M R Pereira, Marilia A Dagostin, Valeria F Caparbo, et al.
Arthritis Care & Research|November 22, 2021
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus ErythematosusEmily F N Yuki, Eduardo F Borba, Sandra G Pasoto, et al.
Journal of Physical Activity & Health|June 8, 2023
No Associations Between Physical Activity and Immunogenicity in SARS-CoV-2 Seropositive Patients With Autoimmune Rheumatic Diseases Prior to and After VaccinationFabiana Infante Smaira, Bruna Caruso Mazzolani, Ítalo Ribeiro Lemes, et al.
Annals of the Rheumatic Diseases|February 9, 2022
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritisAna Cristina Medeiros-Ribeiro, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, et al.
Clinical Rheumatology|June 12, 2023
Robust immunogenicity to the H3N2 component of influenza A vaccine in primary Sjögren syndromeSandra Gofinet Pasoto, Eduardo Ferreira Borba, Francisco Fellipe Claudino Formiga, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|February 10, 2022
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patientsBruno Gualano, Carla G S Saad, Sofia M Sieczkowska, et al.
Rheumatology (Oxford, England)|May 31, 2022
Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccineNadia E Aikawa, Leonard V K Kupa, Clovis A Silva, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2018
Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney OutcomesMeggan Mackay, Maria Dall'Era, Joanna Fishbein, et al.
Pageof 11